<unk>  is indicated for the treatment of adults with relapsed or refractory mantle cell lymphoma. It is also indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Mantle cell lymphoma (MCL) is a rare form of cancerous B-cell non-Hodgkin's lymphoma that usually occurs in middle-aged or older adults. In people with MCL, B-cells, a type of white blood cell which help the body fight infection, change into cancer cells that start to form tumors in the lymph nodes and quickly spread to other areas of the body. Each dose of<unk>  is a customized treatment created using the recipient's own immune system to help fight the lymphoma. The recipient's T cells, a type of white blood cell, are collected and genetically modified to include a new gene that facilitates the targeting and killing of the lymphoma cells. These modified T cells are then infused back into the recipient.
Brexucabtagene autoleucel
Ciltacabtagene autoleucel
Lisocabtagene maraleucel
Belantamab mafodotin
Idecabtagene vicleucel
Levomilnacipran
Nicogel
Dotinurad